Extended-interval dosing of gentamicin for treatment of neonatal sepsis in developed and developing countries.

Abstract

Serious bacterial infections are the single most important cause of neonatal mortality in developing countries. Case-fatality rates for neonatal sepsis in developing countries are high, partly because of inadequate administration of necessary antibiotics. For the treatment of neonatal sepsis in resource-poor, high-mortality settings in developing countries where most neonatal deaths occur, simplified treatment regimens are needed. Recommended therapy for neonatal sepsis includes gentamicin, a parenteral aminoglycoside antibiotic, which has excellent activity against gram-negative bacteria, in combination with an antimicrobial with potent gram-positive activity. Traditionally, gentamicin has been administered 2-3 times daily. However, recent evidence suggests that extended-interval (i.e. >24 hours) dosing may be applicable to neonates. This review examines the available data from randomized and non-randomized studies of extended-interval dosing of gentamicin in neonates from both developed and developing countries. Available data on the use of gentamicin among neonates suggest that extended dosing intervals and higher doses (>4 mg/kg) confer a favourable pharmacokinetic profile, the potential for enhanced clinical efficacy and decreased toxicity at reduced cost. In conclusion, the following simplified weight-based dosing regimen for the treatment of serious neonatal infections in developing countries is recommended: 13.5 mg (absolute dose) every 24 hours for neonates of >2,500 g, 10 mg every 24 hours for neonates of 2,000-2,499 g, and 10 mg every 48 hours for neonates of <2,000 g.

• Authors: Gary L Darmstadt, Mary Miller-Bell, Maneesh Batra, Paul Law, Kiely Law
• Journal: Journal of health, population, and nutrition (J Health Popul Nutr) Vol. 26 Issue 2 Pg. 163-82 (Jun 2008) ISSN: 1606-0997 [Print] Bangladesh
• PMID: 18686550 (Publication Type: Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S., Review)

Chemical References

• Anti-Bacterial Agents
• Gentamicins

Topics

• Anti-Bacterial Agents (therapeutic use)
• Body Weight (physiology)
• Developed Countries
• Developing Countries
• Dose-Response Relationship, Drug
• Drug Administration Schedule
• Female
• Gentamicins (therapeutic use)
• Humans
• Infant, Newborn
• Male
• Sepsis (drug therapy)
• Treatment Outcome